Evaluate the strategy of using data from a novel radiofrequency sensor to manage heart failure compared to a concurrent control group.

• This open-label concurrent-control clinical study demonstrates that a strategy of managing HF with the use of a threshold alert from the HFMS system results in a 38% relative risk reduction in HF readmissions after a HF hospitalization. 
• The percentage of patients who suffered an HF readmission was reduced by an absolute value of 7%, or a number needed to treat of 14.3 patients, to prevent 1 patient from having a HF readmission. 
• A composite endpoint including survival and HF events such as hospitalization and urgent care visits was included as a supplemental analysis and also demonstrated a 38% relative risk reduction. 
• Quality of life, as measured by the KCCQ-12, was improved in the intervention arm, and the magnitude of benefit, 12 points greater improvement than in the control arm, was clinically meaningful.
• The use of HFMS in clinical practice reduces heart failure readmission rates by 29% out to one year.

*FDA registered name: μCor Heart Failure and Arrhythmia Management System

1. Boehmer, J, Cremer, S, Abo-Auda, W. et al. Impact of a Novel Wearable Sensor on Heart Failure Rehospitalization: An Open-Label Concurrent-Control Clinical Trial. J Am Coll Cardiol HF. 2024 Dec, 12 (12) 2011–2022. https://doi.org/10.1016/j.jchf.2024.07.022
2. Boehmer, J. (2025) Reduced heart failure rehospitalization at 1 year for patients wearing a radiofrequency based sensor [Abstract]. In Proceedings of the THT 2025 Conference. Boston, MA. https://www.jacc.org/doi/10.1016/j.jchf.2024.07.022